ADC Therapeutics
ADCT
82 hedge funds and large institutions have $77.3M invested in ADC Therapeutics in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 83 → 82 (-1)
3.09% less ownership
Funds ownership: 58.43% → 55.34% (-3.1%)
31% less capital invested
Capital invested by funds: $112M → $77.3M (-$35.1M)
36% less call options, than puts
Call options by funds: $7K | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$866K |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$723K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$275K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$167K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$92.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$1.9M |
| 2 |
Morgan Stanley
New York
|
-$1.59M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$504K |
| 4 |
Millennium Management
New York
|
-$419K |
| 5 |
Two Sigma Investments
New York
|
-$235K |
ADCT Hedge Fund Activity: Q1 2025 in Review
82 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2025, worth a combined $77.3M — down 31% from $112M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADCT and 12 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 26 added.
The largest buyer was Bank of America, adding an estimated $866K. The largest seller was Woodline Partners, cutting an estimated $1.9M.
- 82 institutional investors held ADC Therapeutics (ADCT) as of Q1 2025, down from 83 in Q4 2024.
- Funds reported $77.3M of ADC Therapeutics stock for Q1 2025, down 31% quarter-over-quarter.
- 12 funds opened new ADC Therapeutics positions in Q1 2025 and 13 closed out, a net change of -1 holder.
- The largest ADC Therapeutics buyer in Q1 2025 was Bank of America, an estimated $866K added.
- The largest ADC Therapeutics seller in Q1 2025 was Woodline Partners, an estimated $1.9M sold.
Based on aggregated 13F filings for Q1 2025.